OSE Immunotherapeutics SA (OSE) AI Stock Analysis

• Market Cap: €129.43M
• Dividend Yield: N/A
• Average Volume (3M): 154.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: -96.92%
• EPS Growth: -175.84%
• Country: FR
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 22,463,263
• 10 Day Avg. Volume: 172,695
• 30 Day Avg. Volume: 154,469
• PEG Ratio: -0.02
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 2.24
• P/FCF Ratio: 3.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €12.50
• Price Target Upside: 101.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: €6.00 ▼(-3.07% Downside)

The overall stock score of 52 reflects the company's improved profitability and operational efficiency, which are offset by declining revenue and negative cash flow growth. Technical indicators suggest a lack of strong momentum, and valuation metrics indicate potential concerns due to ongoing losses and the absence of a dividend yield. The lack of earnings call data and corporate events further limits the assessment.

OSE Immunotherapeutics SA Business Overview & Revenue Model

Company Description

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

How the Company Makes Money

OSE Immunotherapeutics generates revenue primarily through a combination of product development partnerships, licensing agreements, and potential future sales of its therapeutic candidates. The company collaborates with pharmaceutical companies and research institutions to co-develop its products, often receiving milestone payments as products progress through clinical trials. Additionally, OSE may receive royalties from partners on future sales of any successfully commercialized therapies. The company also seeks funding through grants and public offerings to support its research and development efforts. Significant partnerships with larger pharmaceutical companies enhance its revenue potential and provide financial backing for its innovative projects.

OSE Immunotherapeutics SA Financial Statement Overview

Summary

OSE Immunotherapeutics SA has shown significant improvements in profitability and operational efficiency, with a positive net profit margin and improved EBIT and EBITDA margins. The reduction in leverage and positive return on equity are positive signs for financial stability. However, declining revenue and negative free cash flow growth pose challenges for future growth and sustainability.

Income Statement

The company has shown significant improvement in its income statement metrics over the years. The gross profit margin remains strong at 100%, indicating efficient cost management. The net profit margin has improved dramatically from negative values to 53.6% in the latest year, showcasing a turnaround in profitability. However, the revenue growth rate is negative, indicating a decline in sales, which is a concern for future growth. The EBIT and EBITDA margins have also improved significantly, reflecting better operational efficiency.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio has decreased from 2.01 to 0.72, indicating reduced leverage and improved financial stability. Return on equity has turned positive at 58.7%, suggesting effective use of equity to generate profits. However, the equity ratio is not explicitly provided, and the company's total assets have not grown significantly, which could limit future expansion.

Cash Flow

The cash flow statement indicates challenges in maintaining positive cash flow growth. The free cash flow growth rate is negative, reflecting a decline in cash available for reinvestment. However, the operating cash flow to net income ratio is strong at 2.40, indicating good cash generation relative to net income. The free cash flow to net income ratio is nearly 1, suggesting that most of the net income is being converted into free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	69.88M	2.23M	18.30M	26.31M	10.42M
Gross Profit	69.88M	2.23M	18.30M	26.31M	10.42M
EBITDA	41.20M	-17.50M	-13.11M	-13.72M	-18.24M
Net Income	37.45M	-23.00M	-17.76M	-16.85M	-16.55M
Balance Sheet
Total Assets	123.96M	82.05M	91.67M	101.52M	96.85M
Cash, Cash Equivalents and Short-Term Investments	16.75M	18.67M	25.62M	33.58M	29.37M
Total Debt	46.13M	45.80M	44.79M	37.13M	19.51M
Total Liabilities	60.15M	59.08M	59.12M	53.99M	35.61M
Stockholders Equity	63.81M	22.82M	32.55M	47.89M	61.24M
Cash Flow
Free Cash Flow	48.36M	-20.00M	-18.53M	-10.39M	-19.76M
Operating Cash Flow	48.44M	-19.76M	-18.25M	-9.92M	-19.55M
Investing Cash Flow	-46.91M	-507.00K	26.00K	-827.00K	-504.00K
Financing Cash Flow	-3.46M	13.32M	10.27M	14.96M	23.58M

OSE Immunotherapeutics SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.19
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:OSE, the sentiment is Neutral. The current price of 6.19 is below the 20-day moving average (MA) of 6.50, below the 50-day MA of 6.25, and above the 200-day MA of 6.06, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 34.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:OSE.

OSE Immunotherapeutics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OSE	52 Neutral	€129.43M	―	-52.76%	―	-96.92%	-175.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%